Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jnci/djp116 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GrB-Fc-KS49, an anti-EMP2 granzyme B fusion protein therapeutic alters immune cell infiltration and suppresses breast cancer growth.
J Immunother Cancer
December 2024
Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, USA
Background: Granzyme B (GrB) is a key effector molecule, delivered by cytotoxic T lymphocytes and natural killer cells during immune surveillance to induce cell death. Fusion proteins and immunoconjugates represent an innovative therapeutic approach to specifically deliver a deadly payload to target cells. Epithelial membrane protein-2 (EMP2) is highly expressed in invasive breast cancer (BC), including triple-negative BC (TNBC), and represents an attractive therapeutic target.
View Article and Find Full Text PDFLandscape of epithelial cell subpopulations in the human esophageal squamous cell carcinoma microenvironment.
Heliyon
October 2024
Department of Cardiothoracic Surgery, The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, 350025, China.
Article Synopsis
- The study aimed to map out different types of epithelial cell subpopulations within the human esophageal squamous cell carcinoma (ESCC) microenvironment and understand their roles in the development of ESCC.
- Researchers utilized various advanced methods like single-cell RNA sequencing and bioinformatics tools to identify 11 major epithelial cell subpopulations and found 4 specific subgroups linked to significant processes like cell proliferation and immune response.
- Analysis revealed that certain epithelial cells (UBD+ and GAS2L3+) had higher genetic variations and were in different states of differentiation, suggesting their critical involvement in ESCC progression.
A multicomponent nanosystem for capturing circulating tumor cells from cancer patients with PD-L1 as an immunotherapy oncotarget.
J Mater Chem B
October 2024
Actorius Innovations and Research, Pune 411057, India.
Capturing circulating tumor cells (CTCs) from the peripheral blood of cancer patients, where they are disseminated among billions of other blood cells, is one of the most daunting challenge. We report OncoDiscover®, a multicomponent nano-system consisting of iron oxide (FeO) nanoparticles (NPs), polyamidoamine generation 4 dendrimers (PAMAM-G4-NH), graphene oxide (GO) sheets and an anti-epithelial cell adhesion molecule (anti-EpCAM) antibody (Fe-GSH-PAMAM-GO-EpCAM) for the selective and precise capture of CTCs. We further evaluated this system for therapeutically important oncotargets, exemplifying overexpression of the programmed death ligand 1 (PD-L1) as a functional assay on CTCs in cancer patients.
View Article and Find Full Text PDFMHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers.
J Immunother Cancer
September 2024
Immunology and Immunotherapy, Centro de Investigación Médica Aplicada, Pamplona, Spain
Background: Immunodeficient mice engrafted with peripheral blood mononuclear cells (PBMCs) are models to study new cancer immunotherapy agents. However, this approach is associated with xenograft-versus-host disease (xGVHD), which starts early after PBMC transfer and limits the duration and interpretation of experiments. Here, we explore different approaches to overcome xGVHD and better support the development of cancer immunotherapies.
View Article and Find Full Text PDFExploring the potential mechanism of Xiaojin Pill therapy for benign prostatic hyperplasia through metabolomics and gut microbiota analysis.
Front Microbiol
August 2024
School of Pharmacy, Southwest Medical University, Luzhou, China.
Background: Xiaojin Pill (XJP) is a traditional Chinese medicine prescribed for treating benign prostatic hyperplasia (BPH). It has been proven to have multiple effects, such as regulating sex hormone levels, exhibiting anti-tumor, anti-inflammatory, analgesic, and anti-platelet aggregation properties, and improving immunity. However, the material basis of XJP's therapeutic effect on BPH and its metabolic process remains to be clarified.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!